Helius Medical Technologies Surges to 472nd in Trading Volume with $21.5 Million in Shares Exchanged

On June 11, 2025, Helius Medical Technologies (HSDT) saw a significant surge in trading volume, with a total of $21.5 million in shares exchanged, marking a 6108.81% increase from the previous day. This surge placed Helius in the 472nd position in terms of trading volume for the day. The stock price of Helius Medical Technologies (HSDT) rose by 31.36%.

Helius Medical Technologies announced that Aetna Healthcare has authorized an out-of-network claim for its Portable Neuromodulation Stimulator (PoNS®) device. This authorization represents a significant milestone for the company, as it is the third major insurer to provide reimbursement for the PoNS device, following Anthem and United. The PoNS device is a non-invasive therapy that sends mild electrical signals to the tongue through a mouthpiece, aiding in balance and walking ability for individuals with multiple sclerosis.

Helius Medical Technologies is actively pursuing broader third-party coverage for the PoNS device. The company is negotiating reimbursement on a case-by-case basis and aims to align commercial payments with the rates currently offered by the VA/DoD. The authorization from Aetna is seen as an initial step toward achieving this goal. The company's president and CEO, Dane Andreeff, emphasized their commitment to supporting individuals with MS who rely on Medicare for PoNS treatment and their efforts to secure fair and adequate reimbursement by CMS for the PoNS system.

Helius Medical Technologies has a low float of approximately 527,800 shares, which contributes to the stock's volatility. The company's market capitalization was around $446,000 as of the previous trading day. The authorization from Aetna is expected to expand patient access and ensure consistent reimbursement, benefiting the company's continued efforts to secure fair and adequate reimbursement for the PoNS system.